The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Non-infectious Uveitis

In brief

The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.

Key facts

Study ID: NCT00646425
Run by: Cerimon Pharmaceuticals
People needed: 5
Starts: 2008-05-01
Expected to finish: 2008-11-01
Last updated by the study team: 2010-08-19

Who can join

Age: 12 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of noninfectious intermediate, posterior or panuveitis of at least 3 months duration
Treatment with greater than or equal to 20 mg/day of Prednisone at baseline or immunosuppressive drug score of greater than or equal to 5 at baseline
BCVA by ETDRS protocol better than or equal to 20/200
Intraocular pressure of 24 mmHg or less
Anterior chamber cells and vitreous haze of less than or equal to 1
Male or females, aged 12 or greater, body weight of 40 kg or greater

You may not qualify if…

Prior treatment with Retisert
Primary diagnosis of anterior uveitis, uveitis of infectious etiology or Behcet's disease
Pregnancy or breast-feeding
Increase in systemic immunosuppressive treatment regimen within 6 weeks before baseline

Where it is running

Ocular Immunology & Uveitis Foundation — Cambridge, Massachusetts, United States
Tauber Eye Center — Kansas City, Missouri, United States
New York Eye and Ear Infirmary — New York, New York, United States
Southeast Clinical Research Associates — Belmont, North Carolina, United States
University of Texas Medical Branch — Galveston, Texas, United States
Vitreoretinal Consultants — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.